Annual Cash & Cash Equivalents
$23.15 M
-$29.74 M-56.23%
30 September 2022
Summary:
NeuBase Therapeutics annual cash & cash equivalents is currently $23.15 million, with the most recent change of -$29.74 million (-56.23%) on 30 September 2022. During the last 3 years, it has fallen by -$29.74 million (-56.23%).NBSE Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$12.57 M
-$2.18 M-14.76%
30 September 2023
Summary:
NeuBase Therapeutics quarterly cash and cash equivalents is currently $12.57 million, with the most recent change of -$2.18 million (-14.76%) on 30 September 2023.NBSE Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NBSE Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | - | - |
| 3 y3 years | -56.2% | -76.2% |
| 5 y5 years | +124.5% | +21.9% |
NBSE Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | ||||
| 5 y | 5 years | ||||
| alltime | all time | -56.2% | -78.6% |
NeuBase Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2023 | - | $12.57 M(-14.8%) |
| June 2023 | - | $14.75 M(+6.5%) |
| Mar 2023 | - | $13.85 M(-20.4%) |
| Dec 2022 | - | $17.39 M(-24.9%) |
| Sept 2022 | $23.15 M(-56.2%) | $23.15 M(-22.4%) |
| June 2022 | - | $29.85 M(-23.4%) |
| Mar 2022 | - | $38.96 M(-17.7%) |
| Dec 2021 | - | $47.33 M(-10.5%) |
| Sept 2021 | $52.89 M(+65.3%) | $52.89 M(-10.1%) |
| June 2021 | - | $58.84 M(+142.7%) |
| Mar 2021 | - | $24.25 M(-13.3%) |
| Dec 2020 | - | $27.98 M(-12.6%) |
| Sept 2020 | $31.99 M(+210.2%) | $31.99 M(-10.9%) |
| June 2020 | - | $35.92 M(+522.4%) |
| Mar 2020 | - | $5.77 M(-25.3%) |
| Dec 2019 | - | $7.73 M(-25.0%) |
| Sept 2019 | $10.31 M(+4032.2%) | $10.31 M(+624.0%) |
| June 2019 | - | $1.42 M(-33.1%) |
| Mar 2019 | - | $2.13 M(-31.5%) |
| Dec 2018 | - | $3.11 M(+1146.2%) |
| Sept 2018 | $249.60 K(-98.1%) | $249.60 K(-94.4%) |
| June 2018 | - | $4.44 M(-15.0%) |
| Mar 2018 | - | $5.22 M(-40.2%) |
| Dec 2017 | - | $8.72 M(-31.8%) |
| Sept 2017 | $12.80 M(+2.0%) | $12.80 M(-29.2%) |
| June 2017 | - | $18.08 M(+89.9%) |
| Mar 2017 | - | $9.52 M(-29.4%) |
| Dec 2016 | - | $13.49 M(+7.5%) |
| Sept 2016 | $12.55 M(-56.3%) | $12.55 M(-28.8%) |
| June 2016 | - | $17.62 M(-19.5%) |
| Mar 2016 | - | $21.88 M(-13.6%) |
| Dec 2015 | - | $25.33 M(-11.7%) |
| Sept 2015 | $28.70 M(+117.1%) | $28.70 M(-7.4%) |
| June 2015 | - | $30.98 M(-5.6%) |
| Mar 2015 | - | $32.82 M(+214.4%) |
| Dec 2014 | - | $10.44 M(-21.0%) |
| Sept 2014 | $13.22 M | $13.22 M(-11.1%) |
| June 2014 | - | $14.88 M(+328.3%) |
| Mar 2014 | - | $3.47 M(-13.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2013 | - | $4.02 M(-21.6%) |
| Sept 2013 | $5.12 M(+94.6%) | $5.12 M(-15.3%) |
| June 2013 | - | $6.05 M(+242.7%) |
| Mar 2013 | - | $1.77 M(-14.7%) |
| Dec 2012 | - | $2.07 M(-21.4%) |
| Sept 2012 | $2.63 M(+460.3%) | $2.63 M(+82.1%) |
| June 2012 | - | $1.45 M(+86.4%) |
| Mar 2012 | - | $775.30 K(-38.6%) |
| Dec 2011 | - | $1.26 M(+168.7%) |
| Sept 2011 | $469.80 K(+11.2%) | $469.80 K(-46.5%) |
| June 2011 | - | $878.50 K(-20.8%) |
| Mar 2011 | - | $1.11 M(+40.0%) |
| Dec 2010 | - | $792.60 K(+87.6%) |
| Sept 2010 | $422.40 K(-1.9%) | $422.40 K(-29.6%) |
| June 2010 | - | $599.80 K(-16.3%) |
| Mar 2010 | - | $716.90 K(+32.1%) |
| Dec 2009 | - | $542.90 K(+26.1%) |
| Sept 2009 | $430.60 K(+349.5%) | $430.60 K(-34.3%) |
| June 2009 | - | $655.00 K(+8087.5%) |
| Mar 2009 | - | $8000.00(-68.0%) |
| Dec 2008 | - | $25.00 K(-73.9%) |
| Sept 2008 | $95.80 K(-51.4%) | $95.80 K(-39.0%) |
| June 2008 | - | $157.00 K(-42.5%) |
| Mar 2008 | - | $273.00 K(>+9900.0%) |
| Dec 2007 | - | $0.00(-100.0%) |
| Sept 2007 | $197.00 K(>+9900.0%) | $197.00 K(>+9900.0%) |
| June 2007 | - | $0.00(0.0%) |
| Mar 2007 | - | $0.00(0.0%) |
| Dec 2006 | $0.00(0.0%) | $0.00(0.0%) |
| Sept 2006 | - | $0.00(0.0%) |
| June 2006 | - | $0.00(0.0%) |
| Mar 2006 | - | $0.00(0.0%) |
| Dec 2005 | $0.00(0.0%) | $0.00(0.0%) |
| Sept 2005 | - | $0.00(0.0%) |
| June 2005 | - | $0.00(0.0%) |
| Mar 2005 | - | $0.00(0.0%) |
| Dec 2004 | $0.00(0.0%) | $0.00(0.0%) |
| Sept 2004 | - | $0.00(0.0%) |
| June 2004 | - | $0.00 |
| Dec 2003 | $0.00 | - |
FAQ
- What is NeuBase Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for NeuBase Therapeutics?
- What is NeuBase Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for NeuBase Therapeutics?
What is NeuBase Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of NBSE is $23.15 M
What is the all time high annual cash & cash equivalents for NeuBase Therapeutics?
NeuBase Therapeutics all-time high annual cash & cash equivalents is $52.89 M
What is NeuBase Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of NBSE is $12.57 M
What is the all time high quarterly cash and cash equivalents for NeuBase Therapeutics?
NeuBase Therapeutics all-time high quarterly cash and cash equivalents is $58.84 M